Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1291 to 1305 of 2208 results for guidelines

  1. Long-term effects of IVF with or without intracytoplasmic sperm injection in children:- What are the long-term (over 20 years) effects of IVF with or without intracytoplasmic sperm injection (ICSI) in children in the UK?

    little long-term research on the subject. In the review undertaken in this guideline update, the longest length of follow-up in the...

    Research recommendation
    Published
    9 June 2015

  2. HTG EdgeSeq ALKPlus Assay EU for ALK status testing in non-small-cell lung cancer (MIB128)

    NICE has developed a medtech innovation briefing (MIB) on HTG EdgeSeq ALKPlus Assay EU for ALK status testing in non-small-cell lung cancer .

    Medtech innovation briefing
    Published
    7 November 2017

  3. Amitriptyline to prevent recurrent migraine:- Is amitriptyline a clinically and cost effective prophylactic treatment for recurrent migraine?

    that in the International classification of headache disorders II or this guideline. Outcomes should include change in patient‑reported...

    Research recommendation
    Published
    9 August 2021

  4. Chemoprevention to reduce incidence of breast cancer:- A randomised controlled trial is recommended to compare the clinical and cost effectiveness of aromatase inhibitors and tamoxifen for reducing the incidence of breast cancer in women with a family history of breast or ovarian cancer. [new 2013]

    Any explanatory notes(if applicable) Why this is important:- This guideline recommends offering raloxifene or tamoxifen to women at high...

    Research recommendation
    Published
    9 June 2015

  5. What is the effectiveness and cost effectiveness of a trial of hydrolysed formula in formula-fed infants with frequent regurgitation associated with marked distress?

    and/or GORD has not responded to the initial management outlined in this guideline (up to and including alginates). Source guidance...

    Research recommendation
    Published
    9 June 2015

  6. What is the effectiveness, cost effectiveness and safety of the combination of casirivimab and imdevimab for treating COVID-19 in people with particular clinical characteristics (for example, people who are seropositive, of unknown serostatus, immunocompromised, or with specific comorbidities and within both the seropositive and seronegative groups, according to vaccination status or history of natural infection)?

    Source guidance details Comes from guidance COVID-19 rapid guideline: managing COVID-19 Number NG191 Date issued March

    Research recommendation
    Published
    21 October 2021

  7. Robot-assisted surgery for soft tissue procedures: early value assessment (HTG742)

    Early value assessment (EVA) guidance on robot-assisted surgery for soft tissue procedures.

    HealthTech guidance
    Published
    17 April 2025
    View recommendations

    Sections for HTG742

  8. Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy (TA895)

    Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy.

    Technology appraisal guidance
    Published
    7 June 2023
    View recommendations

    Sections for TA895

  9. Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)

    Evidence-based recommendations on tildrakizumab (Ilumetri) for treating moderate to severe plaque psoriasis in adults.

    Technology appraisal guidance
    Published
    17 April 2019
    View recommendations

    Sections for TA575

  10. Tirzepatide for treating type 2 diabetes (TA924)

    Evidence-based recommendations on tirzepatide (Mounjaro) for type 2 diabetes in adults.

    Technology appraisal guidance
    Last updated
    1 September 2025
    View recommendations

    Sections for TA924

  11. Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies (TA786)

    Evidence-based recommendations on tucatinib (TUKYSA) for HER2-positive locally advanced or metastatic breast cancer in adults after 2 or more anti-HER2 treatment therapies.

    Technology appraisal guidance
    Published
    27 April 2022
    View recommendations

    Sections for TA786

  12. Sparsentan for treating primary IgA nephropathy (TA1074)

    Evidence-based recommendations on sparsentan (Filspari) for treating primary immunoglobulin A (IgA) nephropathy in adults.

    Technology appraisal guidance
    Last updated
    9 October 2025
    View recommendations

    Sections for TA1074

  13. ColonFlag for identifying people at risk of colorectal cancer (MIB142)

    NICE has developed a medtech innovation briefing (MIB) on ColonFlag for identifying people at risk of colorectal cancer .

    Medtech innovation briefing
    Published
    12 April 2018

  14. Risk of radiotherapy in people with cancer and COVID-19: Are patients with cancer and COVID-19 who are receiving/have recently received radiotherapy (that is, within the 4 weeks preceding a diagnosis of COVID-19) at increased risk of severe COVID-19 illness or death?

    Source guidance details Comes from guidance COVID-19 rapid guideline: delivery of radiotherapy Number NG162 Date issued

    Research recommendation
    Published
    21 October 2021

  15. Self-management:- What is the impact of different early intervention-focused approaches to self-management on outcomes for older people with social care needs and multiple long-term conditions?

    Any explanatory notes(if applicable) Why this is important:- The Guideline Committee highlighted a lack of evidence on the impact of...

    Research recommendation
    Published
    11 December 2015